Treatment of refractory juvenile dermatomyositis with tacrolimus
© Hassan et al; licensee BioMed Central Ltd. 2008
Published: 15 September 2008
Corticosteroid and second line agents such as methotrexate have dramatically improved the outcome for patients with Juvenile Dermatomyositis (JDM). Nevertheless, some patients suffer persisting disease activity despite these treatments. Tacrolimus, an inhibitor of T-cell activation and proliferation, is one of the new therapeutic options for JDM. However, little is known about its efficacy in this patient group. We report the clinical course of three patients with refractory JDM who were treated with tacrolimus.
Three corticosteroid dependent children with extensive skin disease and severe muscle weakness were started on oral tacrolimus treatment and followed-up for 7–9 months. Patient 1: 11 year old boy, age of onset 6.1 years. Patient 2: 7 year old girl, age of onset 5.8 years. Patient 3: 9 year old girl, age of onset 4.4 years.
Tacrolimus is an effective and safe second line agent in the treatment of chronic refractory JDM and improves the skin involvement substantially.
This article is published under license to BioMed Central Ltd.